CA3218579A1 - Substituted heterocyclic compounds - Google Patents
Substituted heterocyclic compounds Download PDFInfo
- Publication number
- CA3218579A1 CA3218579A1 CA3218579A CA3218579A CA3218579A1 CA 3218579 A1 CA3218579 A1 CA 3218579A1 CA 3218579 A CA3218579 A CA 3218579A CA 3218579 A CA3218579 A CA 3218579A CA 3218579 A1 CA3218579 A1 CA 3218579A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- disease
- mmol
- compound
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US63/188,498 | 2021-05-14 | ||
| US202263318508P | 2022-03-10 | 2022-03-10 | |
| US63/318,508 | 2022-03-10 | ||
| PCT/US2022/029117 WO2022241174A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3218579A1 true CA3218579A1 (en) | 2022-11-17 |
Family
ID=81927791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3218579A Pending CA3218579A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11884650B2 (https=) |
| EP (1) | EP4337648B1 (https=) |
| JP (1) | JP7818623B2 (https=) |
| KR (1) | KR20240008338A (https=) |
| AU (1) | AU2022272725A1 (https=) |
| BR (1) | BR112023023726A2 (https=) |
| CA (1) | CA3218579A1 (https=) |
| ES (1) | ES3059456T3 (https=) |
| IL (1) | IL308422A (https=) |
| MX (1) | MX2023013351A (https=) |
| TW (1) | TW202311248A (https=) |
| WO (1) | WO2022241174A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| KR20240008337A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102233252B1 (ko) * | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| JP7631193B2 (ja) * | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| AU2021254764A1 (en) * | 2020-04-14 | 2022-11-03 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20240008337A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
-
2022
- 2022-05-13 US US17/743,615 patent/US11884650B2/en active Active
- 2022-05-13 MX MX2023013351A patent/MX2023013351A/es unknown
- 2022-05-13 ES ES22727681T patent/ES3059456T3/es active Active
- 2022-05-13 WO PCT/US2022/029117 patent/WO2022241174A1/en not_active Ceased
- 2022-05-13 EP EP22727681.3A patent/EP4337648B1/en active Active
- 2022-05-13 BR BR112023023726A patent/BR112023023726A2/pt not_active Application Discontinuation
- 2022-05-13 IL IL308422A patent/IL308422A/en unknown
- 2022-05-13 AU AU2022272725A patent/AU2022272725A1/en not_active Abandoned
- 2022-05-13 KR KR1020237042732A patent/KR20240008338A/ko active Pending
- 2022-05-13 JP JP2023570166A patent/JP7818623B2/ja active Active
- 2022-05-13 TW TW111118147A patent/TW202311248A/zh unknown
- 2022-05-13 CA CA3218579A patent/CA3218579A1/en active Pending
-
2023
- 2023-12-14 US US18/539,519 patent/US20240124421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4337648B1 (en) | 2025-12-24 |
| AU2022272725A1 (en) | 2024-01-04 |
| IL308422A (en) | 2024-01-01 |
| MX2023013351A (es) | 2023-11-27 |
| EP4337648A1 (en) | 2024-03-20 |
| KR20240008338A (ko) | 2024-01-18 |
| JP2024518555A (ja) | 2024-05-01 |
| US11884650B2 (en) | 2024-01-30 |
| WO2022241174A1 (en) | 2022-11-17 |
| TW202311248A (zh) | 2023-03-16 |
| US20240124421A1 (en) | 2024-04-18 |
| US20220388987A1 (en) | 2022-12-08 |
| BR112023023726A2 (pt) | 2024-01-30 |
| ES3059456T3 (en) | 2026-03-20 |
| JP7818623B2 (ja) | 2026-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884650B2 (en) | Substituted heterocyclic compounds | |
| KR102782807B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| KR102531036B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| EP3917912B1 (en) | Amide-disubstituted pyridine or pyridazine compounds | |
| US10294256B2 (en) | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| US20240270723A1 (en) | Substituted heterocyclic compounds | |
| EP4337650A1 (en) | Substituted heterocyclic compounds | |
| US20240317718A1 (en) | Substituted heterocyclic compounds | |
| CN117321045A (zh) | 经取代的杂环化合物 | |
| EA047032B1 (ru) | Замещенные гетероциклические соединения | |
| CN117355514A (zh) | 经取代的杂环化合物 | |
| WO2024102683A1 (en) | Substituted heterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251031 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251231 |